ArticleFrontiers in microbiology2019
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 73 citations in OpenAlex.
- Co-occurrence of plasmid-mediated colistin resistance gene, mcr-1 and blaScientific reports · 2026Article
- Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector.Pharmaceutical medicine · 2025Review
- Interplay between bacterial clones and plasmids in the spread ofOne health (Amsterdam, Netherlands) · 2025Article
- A review of risk factors at the human-animal-environmental interface of garbage dumps that are driving current and emerging zoonotic diseases.One health (Amsterdam, Netherlands) · 2024Review
- A Systematic Review and Comprehensive Analysis ofAntibiotics (Basel, Switzerland) · 2024Review
- Wild Birds as Drivers ofTransboundary and emerging diseases · 2024Article
- Genetic characterization of multidrug-resistantFrontiers in cellular and infection microbiology · 2024Article
- Synergistic effects of polymyxin and vancomycin combinations on carbapenem- and polymyxin-resistantMicrobiology spectrum · 2023Article
- Carriage and within-host diversity ofEmerging microbes & infections · 2023Article
- Prevalence and Transmission of Extended-Spectrum Cephalosporin (ESC) Resistance Genes inAntibiotics (Basel, Switzerland) · 2023Article
- Mge-cluster: a reference-free approach for typing bacterial plasmids.NAR genomics and bioinformatics · 2023Article
- Prevalence and Genomic Characteristics ofMicrobiology spectrum · 2023Article
- Genomic Surveillance ofAntibiotics (Basel, Switzerland) · 2023Article
- White stork movements reveal the ecological connectivity between landfills and different habitats.Movement ecology · 2023Article
- First Known Report ofInternational journal of environmental research and public health · 2023Article
- Epidemiology and zoonotic transmission ofFrontiers in microbiology · 2023Article
- Worldwide Disseminated IncX4 Plasmid CarryingMicrobiology spectrum · 2022Article
- Screening of colistin-resistant bacteria in livestock animals from France.Veterinary research · 2022Article
- Genomics and pathotypes of the many faces of Escherichia coli.FEMS microbiology reviews · 2022Article
- High Fecal Prevalence ofAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin has become the last-line antimicrobial for the treatment of multidrug resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.